These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 12771887

  • 1. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
    Nguyen DM, Schrump WD, Tsai WS, Chen A, Stewart JH, Steiner F, Schrump DS.
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
    [Abstract] [Full Text] [Related]

  • 2. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
    Shapiro GI, Koestner DA, Matranga CB, Rollins BJ.
    Clin Cancer Res; 1999 Oct; 5(10):2925-38. PubMed ID: 10537362
    [Abstract] [Full Text] [Related]

  • 3. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
    Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, Haimovitz-Friedman A, Schwartz GK.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):6052-61. PubMed ID: 14676132
    [Abstract] [Full Text] [Related]

  • 4. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.
    Litz J, Carlson P, Warshamana-Greene GS, Grant S, Krystal GW.
    Clin Cancer Res; 2003 Oct 01; 9(12):4586-94. PubMed ID: 14555534
    [Abstract] [Full Text] [Related]

  • 5. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
    Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P, Grant S.
    Cancer Res; 2001 Mar 15; 61(6):2583-91. PubMed ID: 11289135
    [Abstract] [Full Text] [Related]

  • 6. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
    Jiang J, Matranga CB, Cai D, Latham VM, Zhang X, Lowell AM, Martelli F, Shapiro GI.
    Cancer Res; 2003 Nov 01; 63(21):7410-22. PubMed ID: 14612540
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y, Rahmani M, Grant S.
    Oncogene; 2003 Oct 16; 22(46):7108-22. PubMed ID: 14562039
    [Abstract] [Full Text] [Related]

  • 8. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
    Patel V, Senderowicz AM, Pinto D, Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS.
    J Clin Invest; 1998 Nov 01; 102(9):1674-81. PubMed ID: 9802881
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
    Schwartz GK, Farsi K, Maslak P, Kelsen DP, Spriggs D.
    Clin Cancer Res; 1997 Sep 01; 3(9):1467-72. PubMed ID: 9815832
    [Abstract] [Full Text] [Related]

  • 10. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
    Pei XY, Dai Y, Grant S.
    Mol Cancer Ther; 2004 Dec 01; 3(12):1513-24. PubMed ID: 15634644
    [Abstract] [Full Text] [Related]

  • 11. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
    Gao N, Dai Y, Rahmani M, Dent P, Grant S.
    Mol Pharmacol; 2004 Oct 01; 66(4):956-63. PubMed ID: 15235103
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.
    Yeow WS, Baras A, Chua A, Nguyen DM, Sehgal SS, Schrump DS, Nguyen DM.
    J Thorac Cardiovasc Surg; 2006 Dec 01; 132(6):1356-62. PubMed ID: 17140955
    [Abstract] [Full Text] [Related]

  • 15. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
    Song Y, Shen K, Tang PP.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Nov 01; 42(11):761-4. PubMed ID: 18307904
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
    Almenara J, Rosato R, Grant S.
    Leukemia; 2002 Jul 01; 16(7):1331-43. PubMed ID: 12094258
    [Abstract] [Full Text] [Related]

  • 18. Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C).
    Maxhimer JB, Reddy RM, Zuo J, Cole GW, Schrump DS, Nguyen DM.
    J Thorac Cardiovasc Surg; 2005 Jan 01; 129(1):53-63. PubMed ID: 15632825
    [Abstract] [Full Text] [Related]

  • 19. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
    Li W, Fan J, Bertino JR.
    Cancer Res; 2001 Mar 15; 61(6):2579-82. PubMed ID: 11289134
    [Abstract] [Full Text] [Related]

  • 20. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
    Jaschke B, Milz S, Vogeser M, Michaelis C, Vorpahl M, Schömig A, Kastrati A, Wessely R.
    FASEB J; 2004 Aug 15; 18(11):1285-7. PubMed ID: 15180955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.